Treatment Access Solution

A collaboration with Novartis

Tasigna® (nilotinib)

The Max Foundation has partnered with Novartis since 2008 to increase access to Tasigna® (nilotinib) for people living with chronic myeloid leukemia (CML). Access to Tasigna® extends to patients who meet program guidelines and are treated in specific low- and middle-income countries.

Throughout 2017 The Max Foundation and Novartis will be transitioning existing access pathways for Tasigna® (nilotinib) to a new collaboration known as CMLPath to Care™.

CMLPath to Care is a unique global initiative that connects people living with chronic myeloid leukemia (CML) and their carers with effective treatments, professional medical capabilities, trained physicians and hands-on support. The initiative is directed by The Max Foundation with support from Novartis Oncology through drug donations and funding. CMLPath to Care is an evolved compact reflecting a new healthcare environment and the founders’ one simple goal – to enable people living with CML to be well.

View our global map and click on individual countries to learn where these programs are operating today. Contact us for more information about how to access Tasigna® (nilotinib) for chronic myeloid leukemia in these countries.

Return to Treatment Access Solutions